Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX10 plus chemoradiotherapy versus placebo plus chemoradiotherapy for limited-stage small cell lung cancer
CTR20220760Phase 3Active
- Sponsor
- HyBioPharma
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of serplulimab in small cell lung cancer (SCLC), sponsored by HyBioPharma. Started May 2022; status: active.
02
Drugs
serplulimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20220760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220760.